RUNX2-guided signaling axes were found to participate in the modulation of several key processes of cancer progression including transdifferentiation and cancer stemness, angiogenesis, cancer cell metastasis, proliferation, and drug resistance. This evidence concerns the gene RUNX2 and cancer.